MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that DiaSorin S.p.A., a worldwide provider of specialty assays, has taken a license for two recombinant HuCAL antibodies. The antibodies, which were made by AbD Serotec, MorphoSys's division for research and diagnostic antibodies, act as recombinant controls for two marketed infectious disease assays. AbD Serotec will receive license fees and royalties on sales of kits comprising the antibodies. Further financial details were not disclosed.
The collaboration between DiaSorin and AbD Serotec brings together DiaSorin’s broad expertise in the development, manufacturing and marketing of immunodiagnostic test systems and AbD Serotec's leading recombinant HuCAL antibody generation technology. AbD Serotec has generated two recombinant antibodies in the IgM format, which DiaSorin is implementing into its new diagnostic tests for Measles IgM and Mumps IgM. The introduction of the DiaSorin LIAISON® Measles IgM and LIAISON® Mumps IgM assays provides the first and only fully automated immunoassays on the diagnostic market for the serological determination of the immunity status of patients to measles and mumps viruses.
“Today’s news is another example of AbD Serotec’s ability to offer superior solutions for diagnostic companies in the quickest possible time using the HuCAL technology”, commented Dieter Feger, Senior Vice President and Head of MorphoSys’s AbD Serotec Division. “Recombinant control antibodies based on our HuCAL technology support the provision of accurate results through effective diagnostic assay management.”
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. The company’s AbD Serotec unit uses HuCAL and other antibody technologies to generate superior monoclonal antibodies for research and diagnostic applications.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 70 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer’s disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla® and Ylanthia® and 100 billion high potentials® are registered trademarks of MorphoSys AG.
Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332